Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ander Mayor

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 8, 2026
Immune checkpoint inhibitor-induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force studyTristan V M Bruijn, Alexandre O Gérard, Maëlys Labat, et al.
Journal of the American Academy of Dermatology|October 6, 2020
Chilblain-like lesions and COVID-19 infection: A prospective observational study at Spain's ground zeroMarta Feito-Rodríguez, Ander Mayor-Ibarguren, Carmen Cámara-Hijón, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 11, 2026
Dermatologic adverse events associated with amivantamab: A multicentre studyVasiliki Nikolaou, Ander Mayor, Vincent Sibaud, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 8, 2026
Immune checkpoint inhibitor-induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force studyTristan V M Bruijn, Alexandre O Gérard, Maëlys Labat, et al.
Journal of the American Academy of Dermatology|October 6, 2020
Chilblain-like lesions and COVID-19 infection: A prospective observational study at Spain's ground zeroMarta Feito-Rodríguez, Ander Mayor-Ibarguren, Carmen Cámara-Hijón, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 11, 2026
Dermatologic adverse events associated with amivantamab: A multicentre studyVasiliki Nikolaou, Ander Mayor, Vincent Sibaud, et al.
Pageof 3